BioCryst Pharmaceuticals (NASDAQ:BCRX) resolved a pediatric Orladeyo manufacturing delay with pellets due early August while preserving FY revenue guidance and trimming 2026 operating expense outlook as it winds down Birmingham; Cantor raised its price target and the company granted inducement equity to new hires.
Previous Week Recap
- Orladeyo Pellets Milestone Reached: BioCryst (BCRX) cleared a manufacturing delay for pediatric Orladeyo pellets; product due early August. Company focuses on navenibart (top-line Q3 2027) and BCX17725 (POC by end‑2026).
- FY Guidance Maintained, Costs Cut: BioCryst (BCRX) kept FY revenue guidance, cut adjusted operating expense outlook to $420M–$440M (from $450M–$470M), and plans additional cost cuts tied to winding down its Birmingham facility.
- Cantor Raises Price Target: Cantor Fitzgerald raised BioCryst Pharmaceuticals (BCRX) price target to $29 from $27, a $2 increase in the firm’s valuation of the stock; no further commentary was provided.
- Inducement Equity To Nine Hires: July 1, 2026: BioCryst (BCRX) granted inducement equity to nine hires — options for 33,950 shares at $9.65 (10‑yr, four‑year vesting) and 91,750 RSUs with same vesting.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.